# A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

> **NCT01222455** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (estimated)

## Conditions studied

- Hepatic Impairment
- Healthy Volunteers
- Pharmacokinetics
- Amount of R406 in Blood

## Interventions

- **DRUG:** Fostamatinib

## Key facts

- **NCT ID:** NCT01222455
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2011-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01222455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01222455, "A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01222455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*